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Abstract: Introduction: Considering the incidence of contrast induced nephropathy (CIN) as well as its complications
and costs, prevention and reducing the risk of CIN is an essential issue. The present study aimed to evaluate
the efficacy of vitamin E and N-acetylcysteine (NAC) on the prevention of CIN in diabetic patients undergo-
ing coronary angiography. Methods: 360 patients with diabetes who required angiography, including patients
with stable angina susceptible to acute myocardial infarction and patients with acute coronary syndrome were
included and randomized into three groups . Group 1 received serum therapy (Normal Saline) plus NAC and
placebo of vitamin E, group 2 received serum therapy plus vitamin E and placebo of NAC, and group 3 only
received serum therapy with two placebos of NAC and vitamin E. The groups were compared considering CIN
after angiography. Results: A total of 93 patients were studied in group 1, 94 in group 2, and 113 in group 3. CIN
occurred in 4 patients (4.3%), 4 patients (4.3%), and 8 patients (7.1%) in groups 1, 2, and 3, respectively (P=0.58).
There was a significant difference in mean difference of creatinine levels before and after study in groups 1 and 2
(both P<0.001). In the subgroup of patients with chronic kidney disease, NAC significantly reduced CIN (P=0.03).
Conclusion: The results suggested efficacy of both interventions, considering reduction of mean Serum crea-
tinine ( Scr) after the study, while lack of significant difference in the incidence of CIN could be because of the
low number of CIN in our study. The second important finding of this study, probably the reduced risk of CIN
in diabetic patients with chronic kidney disease receiving NAC, recommends the use of NAC for prevention of
CIN, especially in this subgroup of patients undergoing angiography.
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1. Introduction
Contrast induced nephropathy (CIN), also known as
contrast-induced acute kidney injury (AKI), which refers
to the deterioration of renal function because of iodine
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contrast media (ICM), is the third most common cause of
hospital acquired acute renal injury (1) that can increase
the length of hospitalization, costs, and patients’ morbidity
and/or mortality (2). The exact mechanism of CIN is not
completely understood, while it has been suggested to be
related to the renal vasoconstriction or direct cytotoxic
effects, induced by ICM, resulting in hypoxic injury to the
renal tubules (3). However, ICM is essential to many diag-
nostic and therapeutic procedures, such as angiography and
cardiac interventions (4).
The most commonly used method for assessing CIN is >0.5
mg/dL or 25% increase in serum creatinine (Scr) levels from
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baseline level within 48 hours; according to this definition,
the incidence of CIN is reported in about <1% to 50% of the
general population, varying according to the presence of
(one or combination of) risk factors in the patients (1). The
most important risk factors of CIN include advanced age,
baseline chronic renal failure (CRF), congestive heart failure,
and diabetes mellitus (DM), and other risk factors include
anemia, left ventricular dysfunction and hypotension, renal
transplant, low serum albumin, and concomitant use of
nephrotoxins (5). DM is considered an important risk factor
due to the susceptibility of diabetic kidney to intensified hy-
poxic and oxidative stress (6). Accordingly, special attention
should be paid to patients with risk factors when the patient
is scheduled for an intervention with injection of ICM (7).
Preventive measures, such as reducing the modifiable risk
factors, pre-procedural hydration, and adjusting the volume
and type of ICM based on patient’s conditions have been
suggested to reduce the risk of CIN (8). Additionally, several
pharmacologic agents have been investigated, with special
attention on vitamins and other antioxidant agents (9). Vi-
tamin E (α- and γ-tocopherol) has been suggested as a new
strategy of CIN prevention (10, 11). N-acetylcysteine (NAC),
a thiol-containing antioxidant, has been suggested to reduce
the risk of CIN; nevertheless, the results of comparing its
efficacy with hydration are controversial: two meta-analyses
showed significant efficacy of NAC on CIN prevention,
compared to hydration (12, 13), while another study with
meta-analysis showed no significant efficacy of intravenous
NAC with a large heterogeneity among the results of studies
in this regard (14). Another meta-analysis concluded that
NAC can prevent CIN in patients undergoing coronary, but
not peripheral angiography (15).
According to the controversial results, the limitations of
previous studies, and considering the high incidence of CIN
after coronary angiography (CA) or angioplasty (about 12%)
in Iranian patients (16), as well as the important of DM as
risk factor of CIN (6) and high prevalence of DM in Iran
(17), in the present study, we selected a sample of Iranian
patients undergoing diagnostic CA, and aimed to evaluate
the efficacy of vitamin E and NAC on prevention of CIN in
diabetic patients undergoing diagnostic CA in a randomized
placebo-controlled clinical trial.
2. Materials and Methods
2.1. Study design
The protocol of this study is registered in the Ira-
nian Registry of Clinical Trials (IRCT) with the code
IRCT20200417047114N1. Adult diabetic patients who
referred to Shahid Modarres and Shahid Rajaei hospitals
in Tehran, Iran, from June 2019 to May 2020 for diagnostic
CA were considered as the study population of the present
randomized placebo-controlled double-blind clinical trial.
All patients with DM type I and II, according to the medical
records, were included. Diagnostic CA was indicated at these
centers for patients with stable angina susceptible to acute
myocardial infarction and patients with acute coronary
syndrome. Any patient with sensitivity to ICM, cardiogenic
shock, acute myocardial infarction, pulmonary edema, acute
renal failure (ARF), , pregnancy, and patients on nutine
hemodialysis and patients with acute coronary syndrome,
who underwent CA or angioplasty or injected any other ICM
in the past 5 days were not included into the study. Patients
with chronic kidney disease (CKD), who had glomerular fil-
tration rate (GRF) of <30 mL/min were not included into the
study. the research team referred to the patients, explained
the objectives, the study protocol and steps, and risks and
benefits of the administered drugs, etc. and asked them to
read and sign the written informed consent form.
The recruited patients were randomized by randomiza-
tion table into three equal groups, each group comprising
120 participants. The randomization was generated by
an analyst, not involved in other study steps, who pro-
vided 360 coded envelopes to the nurses. Neither the
nurses/physicians who prescribed the drugs to the patients,
nor the patients were aware of the allocations. In all patients
on metformin, drug hold from 72 h before intervention.
Group 1 received serum therapy (Normal Saline) plus NAC
and placebo of vitamin E, group 2 received serum therapy
plus vitamin E and placebo of NAC, and group 3 only re-
ceived serum therapy with two placebos of NAC and vitamin
E. The drugs were prepared by ZAHRAVI Pharmaceuti-
cal Company. The serum therapy included infusion of 1
cc/kg/hr 0.9% sodium chloride serum, from 12 hours before
until 12 hours after CA. NAC tablets (1200mg) were given to
the patients 2 hours before and 4 hours after the CA; 600mg
vitamin E was given to the patients 2 hours before and 40 mg
4 hours after CA.
Demographic characteristics of the participants, including
age, sex, BMI, and risk factors, such as hypertension, dys-
lipidemia, smoking status, history of bypass cardiac surgery,
type of DM, CKD, and the drugs the patients used were
recorded by taking patients’ medical history. On the day of
admission, the ward’s nurse measured the patients’ height,
weight, and vital signs, including systolic and diastolic blood
pressure (measure in sitting position from the left hand)
and recorded the patients’ heart rate (HR) based on the
electrocardiogram results and ejection fraction (EF) based
on the results of echocardiography, performed on admission
day. One 8-hour fasting venous blood sample was taken
from all participants 8 hours before CA and another 48 hours
after CA., and sent to the laboratory for measurement of the
baseline serum values of white blood cell (WBC), platelet,
hemoglobin (Hb), fasting and non-fasting blood sugar, very
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low, low, and high density lipoprotein (VLDL, LDL, and
HDL), total cholesterol (TC), triglyceride (TG), blood urea
nitrogen (BUN) and Cr , sodium (Na), and potassium (K)
were recorded. The exact value of ICM was also recorded for
each patient.
The primary outcome of the study was considered as the
incidence of CIN, defined as >0.5 mg/dL or 25% increase
in serum creatinine (Scr) levels from baseline level within
48 hours; the secondary outcome was considered as the
Scr levels and GFR before and after the intervention. The
patients’ GFR was calculated. Visipaque contract agent was
used for all patients.
2.2. Statistical analysis
Results were presented as mean ± standard deviation (SD)
for quantitative variables and were summarized by frequency
(percentage) for categorical variables. Categorical variables
were compared using chi-square test or Fisher’s exact test.
One–sample Kolmogorov–Smirnov test was used to deter-
mine the normal distribution of data and Levene’s test was
used to test the equality of variances. Continuous variables
were compared using one way ANOVA or Kruskal-Wallis H
test, whenever the data did not appear to have normal distri-
bution or when the assumption of equal variances was vio-
lated across the study groups. For the statistical analysis, the
statistical software IBM SPSS Statistics for Windows version
21.0 (IBM Corp. 2012. Armonk, NY: IBM Corp.) was used. P
values of 0.05 or less were considered statistically significant.
3. Results
A total of 300 patients completed the study; 93 patients in
group 1, 94 patients in group 2, and 113 patients in group 3
(Figure 1). The demographic characteristics (age, sex, BMI)
of the three study groups and the frequency of hyperten-
sion, dyslipidemia, smoking status, history of bypass cardiac
surgery, type of DM, and CKD, baseline values of systolic and
diastolic blood pressure, number of heart rate (HR), ejection
fraction (EF), and the drugs the patients used were not differ-
ent among the groups (P>0.05; table 1).
Comparing the results of baseline serum parameters showed
significant differences among the three study groups in mean
values of LDL, VLDL, and TC (P=0.018, 0.033, and 0.04, re-
spectively), while other serum parameters were not different
(P>0.05; table 2).
Mean ±SD of ICM was 40± 23 cc , 42±12 cc , and 45±13 cc
in groups 1, 2, and 3, respectively (P=0.43). The frequency of
CIN was 4.3% (N=4), 4.3% (N=4), and 7.1% (N=8) in groups
1, 2, and 3, respectively (P=0.58), as the results of chi square
test showed. Pairwise comparison between the groups us-
ing Fisher’s exact test showed no difference between groups
1 and 2 (P=1), 1 and 3 (P=0.55), and 2 and 3 (P=0.55).
Mean ±SD of Scr levels of the participants before and after
the intervention are shown in table 3. As demonstrated, there
was a significant difference in mean Scr levels after the in-
tervention among the three groups (P=0.043) with significant
difference between groups 1 and 2 (P=0.04). The mean dif-
ference of Scr (after intervention vs. before intervention) was
also different among the three study groups (P=0.001) with
significant difference between groups 1 and 3 and between
groups 2 and 3 (both P<0.001). Although the difference in
mean Scr was not clinically significant.
4. Discussion
The results of the present study showed a prevalence of 5.3%
in diabetic patients without severe CKD who underwent di-
agnostic CA, which is much higher than the rate reported in
a previous study on Iranian patients undergoing CA or an-
gioplasty (12%) (16). It is well known that the incidence of
CIN depends on the presence of risk factors and the two most
important risk factors of CIN includes CKD and DM (18). It
has been suggested that the defective diabetic kidneys have a
higher vulnerability to renal damage, hypoxia, and oxidative
stress, induced by ICM (6) that results in about increase in
the risk of CIN in diabetic patients with normal GFR (19). In
a previous study on 155 diabetic patients, undergoing CA or
angioplasty, CIN occurred in about 26% of diabetic patients
(20). Also, in another study on 114 diabetic patients who un-
derwent percutaneous coronary intervention (PCI), CIN was
observed in 18.4% of the patients (21). The incidence of CIN
in the above-mentioned studies (20, 21) are higher than that
of the present study, which determines the effectiveness of
the interventions used in the present study. Furthermore, the
discrepancy in the results of studies can be due to the base-
line renal function of the study subjects, which play a signif-
icant role in the susceptibility to CIN (19, 22). In this study,
we included patients with GFR >30 ml/min and did not in-
clude patients with ARF to minimize the effect of this con-
founder on the study results. In another study on diabetic
patients undergoing elective cardiac catheterization or PCI,
the results reported the CIN rate at 5.2% (22), which is close
to the results of the present study.
Hydration has been suggested as an important component
for CIN prevention, recommended to be used in all patients
receiving ICM, especially those with risk factors (23). How-
ever, hydration does not eliminate this risk and CIN is still
observed in 13-28% of patients undergoing CA, despite suffi-
cient hydration (24). Accordingly, complementary interven-
tions are suggested. The results of our study showed that
administration of NAC or vitamin E plus hydration resulted
in 4.3% CIN, while hydration alone resulted in 7.1% CIN
without statistically significant difference among the study
groups; however, the authors suggest that the lack of statis-
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tical significant in the incidence of CIN is because of the low
frequency of CIN, as we have observed a significant differ-
ence in the before-after difference in Scr levels among the
study groups: Scr levels increased in the control group after
the study, while it decreased in the two intervention groups
with statistically significant difference, compared to the con-
trol group. This finding shows the significant efficacy of both
of the interventions, namely NAC and vitamin E on renal
function of diabetic patients. The results of previous stud-
ies on the preventive effect of NAC are controversial. Sar
and colleagues evaluated the efficacy of addition of 1200mg
NAC to hydration with saline in patients with type II DM and
showed that it resulted in reduction of Scr from 0.83 to 0.79
(mean values), while Scr increased in the control group (25).
These results are consistent with the results of the present
study. In the study by Berwanger et al, evaluation of 1395 di-
abetic patients undergoing coronary and peripheral angiog-
raphy showed that administration of 1200 mg oral NAC (once
before and once after angiography) could not reduce the in-
cidence of CIN (14.7% in NAC group vs. 13.8% in the control
group) (26), which confirms the results of the present study,
although the CIN rates were much higher in their study, com-
pared to that reported in the current study.
One of the most important risk factors of CIN is CKD and sev-
eral studies have investigated the efficacy of agents reducing
the risk of CIN in these subgroup of patients (13, 15). The re-
sults of subgroup analysis in the present study showed that
NAC could significantly reduce the risk of CIN in subgroup
of patients with CKD, compared to the control group, which
is consistent with the results of the study by Carbonell et al.,
suggesting the incidence of CIN at 5.1% in the group receiv-
ing NAC, vs. 23.8% in the control group (27), although they
have not focused on diabetic patients. On the other hand,
other studies suggest no efficacy for 600 mg oral NAC twice a
day (28) or intravenous injection of 600 mg NAC (29) on pre-
vention of CIN, compared to hydration of patients by normal
saline in high-risk patients (with baseline Scr >1.5 mg/dL)
undergoing elective CA. This discrepancy in the results of the
studies could be due to the difference in the frequency of
other risk factors that confound the results. One of the im-
portant influential factors is the volume of ICM and the re-
sults of our study showed that the three groups had no sig-
nificant difference in mean ICM. Also, our results showed the
similarity of the study groups in terms of other influential fac-
tors suggested, such as mean arterial blood pressure, and the
use of medications, like diuretics and vasoactive agents (30).
The results of our study also showed the significant reduc-
tion of Scr in the group receiving vitamin E, compared to the
control group. But, we could not find any other study investi-
gating the effect of vitamin E on prevention of CIN in diabetic
patients and previous studies have only considered CKD pa-
tients. In the subgroup of patients with CKD in the present
study, we did not observe significant difference in the inci-
dence of CIN. These results are consistent with the results of
the study by Kitzler et al., which showed no difference in the
incidence of CIN in CKD patients receiving vitamin E, com-
pared to hydration with sodium chloride (31). This is while,
other studies on patients with CKD have shown significant
effect of vitamin E (α- and γ-tocopherol) on reduction of CIN
rates (10, 11, 32), confirmed by the meta-analysis on the four
studies (33). The discrepancy in the results of studies could
be due to the fact that they have not focused on diabetic pa-
tients. One of the limitations of the present study was the
variability of the ICM volume that could be a confounder.
Furthermore, we enrolled the patients into the study by non-
randomized method and from one city (Tehran, center of
Iran), which increased the risk of bias in the study results. It
has to be mentioned that we did not follow the patients, as
the study objectives was centered on ARF, while studying the
long-term follow-up outcomes of patients can conclude dif-
ferent results.
5. Conclusion
In conclusion, the results of the present study suggested the
efficacy of both interventions, considering the reduction of
mean Scr after the study. Although, none of them could re-
duce the incidence of CIN clinically, which could be due to
the low number of CIN in our study. The second important
finding of this study, the reduced risk of CIN rise of Cr in di-
abetic patients with CKD receiving NAC, although the differ-
ence was not clinically significant, recommends the use of
NAC for prevention of CIN, especially in this subgroup of pa-
tients undergoing angiography. Considering the fact that sev-
eral risk factors can affect the incidence of CIN, further stud-
ies are required to examine the exact effect of these supple-
ments on different subgroups of diabetic patients.
6. Limitations
In this study, according to the formula, were to get included
near to 500 patients, but due to lack of sufficient time and
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Table 1: Comparing the demographic and clinical characteristics among the three study groups.
Variable Categories Group 1 (N=93) Group 2 (N=94) Group 3 (N=113) p-value
Age (years), mean ±SD 65± 8.9 65± 9.3 64± 7.4 0.58*
Sex, No. (%) Male 72(77.4) 66(70.2) 78(69) 0.37†
Female 21(22.6) 28(29.8) 35(31)
Weight (kg), mean ±SD 78±11 78±12 78±12 0.86*
Height (m), mean ±SD 167±7.9 166±9.3 166±12 0.75*
BMI (kg/m2), mean ±SD 27±13 28±30 28±28 0.68*
Hypertension, No. (%) 64(68.8) 63(67) 60(53.1) 0.071
Systolic blood pres-
sure (mmHg),
mean ±SD 125±12 126±14 127±11 0.50*
Diastolic blood pres-
sure (mmHg),
mean ±SD 77±7.1 78±7.8 77±6.6 0.87*
Heart rate (/min), mean ±SD 72±10 72±10 73±10 0.52*
Dyslipidemia, No. (%) 44(47.3) 43(45.7) 55(48.7) 0.91†
Smoker, No. (%) 34(36.6) 42(44.7) 48(42.5) 0.50†
Positive history of by-
pass cardiac surgery,
No. (%) 19(20.4) 13(13.8) 21(18.6) 0.47†
Ejection fraction (%), mean ±SD 48±4.8 47±4.6 50±4.4 0.74*
Chronic kidney dis-
ease,
No. (%) 4(4.2) 3(3.1) 5(4.4) 0.21†
Diabetes type I, No. (%) 47(50.5) 50(53.2) 60(53.1) 0.91†
Diabetes type II, No. (%) 46(49.5) 44(46.8) 53(46.9)
Drug history, Aspirin/Plavix 87(93.5) 87(92.6) 103(93.8) 0.93†
No. (%) Atorvastatin 88(94.6) 85(90.4) 105(93.8) 0.49†
Captopril 24(25.5) 23(24.7) 25(22.1) 0.73†
Losartan 45(47.87) 45(47.3) 47(41.59) 0.94†
metformin 60±32.3 58±45.3 65±42.4 0.76
*The results of one way ANOVA; †The results of chi square test; p-values <0.05 are considered significant.
Table 2: Comparing the results of serum parameters before intervention among the three study groups.
Serum Parameter Group 1 (N=93) Group 2 (N=94) Group 3 (N=113) p-value*
White blood cell 7963±1877 9269±1084 9267±1143 0.53
Platelet count 232819±64697 214223±55754 227415±62499 0.10
Hemoglobin (mg/dL) 13.8±1.6 14±1.7 14±1.7 0.23
Fasting blood sugar (mg/dL) 129±56 137±58 127±58 0.48
Non-fasting blood sugar
(mg/dL)
196±103 178±93 178±94 0.33
Total cholesterol (mg/dL) 136±48 154±49 150±57 0.04
LDL (mg/dL) 67±18 74±16 74±20 0.018
HDL (mg/dL) 41±9.2 40±1.1 43±1.3 0.23
VLDL (mg/dL) 50±21 53±15 57±17 0.033
Triglyceride (mg/dL) 192±61 208±63 200±71 0.27
Blood urea nitrogen
(mg/dL)
19±8.6 18±6.3 17±5.9 0.13
Sodium (meq/dL) 135±18 136±13 138±2.7 0.33
Potassium (meq/dL) 4±0.5 4±2.6 4±2.7 0.41
Cr (mg/dl) 1.37±0.20 1.38±0.22 1.31±0.16 0.18
*The results of one way ANOVA; all values are reported as mean ±SD p-values <0.05 are considered significant.
LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; VLDL: Very Low Density Lipoprotein
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jmp.iums.ac.ir
M. Pishgahi et al. 8
Table 3: Comparing the results of serum creatinine levels before and after intervention among the three study groups.
Serum Creatinine level Group 1 (N=93) Group 2 (N=94) Group 3 (N=113) p-value*
Before intervention 1.37±0.20 1.38±0.22 1.31±0.16 0.18
After intervention 1.29±0.28 1.32±0.30 1.39±0.30 0.043
After vs. before intervention -0.086±0.26 -0.06±0.27 0.08±0.23 0.001
*The results of one way ANOVA; all values are reported as mean ±SD; p-values <0.05 are considered significant.
Pairwise comparison by posthoc test showed significant difference in serum creatinine levels after intervention between groups 1
and 2 (P=0.04) and in mean difference between groups 1 and 3 and between groups 2 and 3 (both P<0.001).
Figure 1: Flow diagram for participant screening and enrollment for this study.
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